PE20060646A1 - Derivados de bencimidazol como moduladores de la actividad de quimioquinas - Google Patents

Derivados de bencimidazol como moduladores de la actividad de quimioquinas

Info

Publication number
PE20060646A1
PE20060646A1 PE2005000940A PE2005000940A PE20060646A1 PE 20060646 A1 PE20060646 A1 PE 20060646A1 PE 2005000940 A PE2005000940 A PE 2005000940A PE 2005000940 A PE2005000940 A PE 2005000940A PE 20060646 A1 PE20060646 A1 PE 20060646A1
Authority
PE
Peru
Prior art keywords
methyl
rent
tetrahydro
binding
quinolinamide
Prior art date
Application number
PE2005000940A
Other languages
English (en)
Inventor
Kristjan Gudmundsson
Paul Richard Sebahar
Leah D Auroroa Richardson
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of PE20060646A1 publication Critical patent/PE20060646A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE BENCIMIDAZOL DE FORMULA (I), EN DONDE t ES 0, 1 O 2; R ES H, ALQUILO, ENTRE OTROS; R2 ES H, ALQUILO, OPCIONALMENTE SUSTITUIDO, HALOALQUILO, CICLOALQUILO, ENTRE OTROS; R3 ES H O ALQUILO OPCIONALMENTE SUSTITUIDO; m ES 0, 1 O 2; R4 ES HALOGENO, HALO ALQUILO, ENTRE OTROS; p ES 0 O 1; Y ES C(O), -N(R10)-, -O-, -S-, -C(O)NR10-, ENTRE OTROS; X ES -RaN(R10)2-, -AyRaN(R10)2, -Het, -RaHet, -HetN(R10)2, ENTRE OTROS. SON PREFERIDOS: N-[2-(1H-IMIDAZOL-4-IL)ETIL]-1-METIL-2-{[METIL(5,6,7,8-TETRAHIDRO-8-QUINOLINIL)AMINO]METIL}-1H-BENCIMIDAZOL-7-CARBOXIAMIDA, N-METIL-N-{[4-(1-PIPERAZINIL)-1H-BENCIMIDAZOL-2-IL]METIL}-5,6,7,8-TETRAHIDRO-8-QUINOLINAMIDA, N-METIL-N-({4-[3-(1-PIRROLIDINIL)PROPIL]-1H-BENCIMIDAZOL-2-IL}METIL)-5,6,7,8-TETRAHIDRO-8-QUINOLINAMIDA, ENTRE OTROS. TAMBIEN SE REFIERE A UN PROCESO DE ELABORACION Y A UNA COMPOSICION FARMACEUTICA. ESTOS COMPUESTOS SON PROTECTORES SOBRE CELULAS DE BLANCO CONTRA INFECCION POR VIH, DEBIDO A QUE SE UNEN ESPECIFICAMENTE AL RECEPTOR DE QUIMIOQUINA Y QUE AFECTA LA UNION DEL LIGANDO NATURAL O QUIMIOQUINA Y AFECTA LA UNION DEL LIGANDO NATURAL O LA QUIMIOQUINA A UN RECEPTOR, TAL COMO CXCR4 Y/O CCR5, EN UNA CELULA DE BLANCO
PE2005000940A 2004-08-16 2005-08-12 Derivados de bencimidazol como moduladores de la actividad de quimioquinas PE20060646A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US60192804P 2004-08-16 2004-08-16

Publications (1)

Publication Number Publication Date
PE20060646A1 true PE20060646A1 (es) 2006-08-04

Family

ID=35968075

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2005000940A PE20060646A1 (es) 2004-08-16 2005-08-12 Derivados de bencimidazol como moduladores de la actividad de quimioquinas

Country Status (18)

Country Link
US (1) US20080045537A1 (es)
EP (1) EP1789045A2 (es)
JP (1) JP2008510006A (es)
KR (1) KR20070042568A (es)
CN (1) CN101039672A (es)
AR (1) AR050522A1 (es)
AU (1) AU2005277638A1 (es)
BR (1) BRPI0514438A (es)
CA (1) CA2577100A1 (es)
IL (1) IL181160A0 (es)
MA (1) MA28814B1 (es)
MX (1) MX2007001958A (es)
NO (1) NO20071161L (es)
PE (1) PE20060646A1 (es)
RU (1) RU2350604C2 (es)
TW (1) TW200619217A (es)
WO (1) WO2006023400A2 (es)
ZA (1) ZA200701282B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7728026B2 (en) 2005-04-11 2010-06-01 Abbott Laboratories, Inc. 2-substituted-1 h-benzimidazile-4-carboxamides are PARP inhibitors
PT1942108E (pt) 2005-10-28 2013-10-24 Ono Pharmaceutical Co Composto com um grupo básico e a sua utilização
US8168783B2 (en) 2005-11-18 2012-05-01 Ono Pharmaceutical Co., Ltd. Chemokine receptor antagonists and use thereof
US8618122B2 (en) 2006-05-16 2013-12-31 Ono Pharmaceutical Co., Ltd. Compound having acidic group which may be protected, and use thereof
WO2008016006A1 (en) 2006-07-31 2008-02-07 Ono Pharmaceutical Co., Ltd. Compound having cyclic group bound thereto through spiro binding and use thereof
GB0702695D0 (en) * 2007-02-12 2007-03-21 Ark Therapeutics Ltd Production of vectors
CL2008002242A1 (es) * 2007-07-31 2009-08-21 Bayer Cropscience Ag Compuestos derivados de n-cicloalquil-n-carboxamida, tiocarboxamida, biciclicas o derivados de carboximidamida n-sustituida; composicion fungicida; y metodo para controlar los hongos fitopatogenos de los cultivos.
WO2010098866A1 (en) 2009-02-27 2010-09-02 Supergen, Inc. Cyclopentathiophene/cyclohexathiophene dna methyltransferase inhibitors
JP5541454B2 (ja) * 2009-09-16 2014-07-09 Ｊｓｒ株式会社 液晶配向剤および液晶表示素子
JP5712524B2 (ja) * 2009-10-28 2015-05-07 Jsr株式会社 液晶配向剤および液晶表示素子
MA34591B1 (fr) 2010-10-06 2013-10-02 Glaxosmithkline Llc Dérivés de benzimidazole utilisés comme inhibiteurs de pi3 kinase
CN102675305B (zh) * 2011-03-08 2014-11-12 中国科学院上海药物研究所 一类咪唑并吡啶类化合物及其制备方法和用途
CN103570683B (zh) * 2012-07-30 2018-04-17 中国科学院上海药物研究所 多取代胺类化合物及其制备方法和用途
WO2017106332A1 (en) 2015-12-14 2017-06-22 X4 Pharmaceuticals, Inc. Methods for treating cancer
US10953003B2 (en) 2015-12-14 2021-03-23 X4 Pharmaceuticals, Inc. Methods for treating cancer
ES2935834T3 (es) 2015-12-22 2023-03-10 X4 Pharmaceuticals Inc Métodos para tratar enfermedad de inmunodeficiencia
WO2017177230A1 (en) 2016-04-08 2017-10-12 X4 Pharmaceuticals, Inc. Methods for treating cancer
CA3027498A1 (en) 2016-06-21 2017-12-28 X4 Pharmaceuticals, Inc. Cxcr4 inhibitors and uses thereof
EP3472129A4 (en) 2016-06-21 2019-12-04 X4 Pharmaceuticals, Inc. CXCR4 INHIBITORS AND USES THEREOF
CN109640988A (zh) 2016-06-21 2019-04-16 X4 制药有限公司 Cxcr4抑制剂及其用途
IL292923B2 (en) 2017-02-21 2024-05-01 Univ Emory CXCR4 cytokine receptor modulators and related uses
EP3687540A4 (en) * 2017-09-25 2021-04-21 CGeneTech (Suzhou, China) Co., Ltd. HETEROARYL COMPOUNDS USED AS CXCR4 INHIBITORS, COMPOSITION AND METHOD OF USE THEREOF
US11396501B2 (en) * 2017-09-25 2022-07-26 Cgenetech (Suzhou, China) Co., Ltd. Heteroaryl compounds as CXCR4 inhibitors, composition and method using the same
US11649235B2 (en) 2018-03-19 2023-05-16 Emory University Pan-tropic entry inhibitors
US10548889B1 (en) 2018-08-31 2020-02-04 X4 Pharmaceuticals, Inc. Compositions of CXCR4 inhibitors and methods of preparation and use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6864265B2 (en) * 2000-09-15 2005-03-08 Anormed, Inc. Chemokine receptor binding heterocyclic compounds
ATE420873T1 (de) * 2000-09-15 2009-01-15 Anormed Inc Chemokin rezeptor bindenden heterozyklische verbindungen
JP2004512336A (ja) * 2000-09-15 2004-04-22 アノーメッド　インコーポレイティド ケモカインレセプター結合複素環式化合物
ES2269465T3 (es) * 2000-09-15 2007-04-01 Anormed Inc Compuestos heterociclicos de union a los receptores de la quimioquina.
IL161784A0 (en) * 2001-12-21 2005-11-20 Anormed Inc Chemokine receptor binding heterocyclic compounds with enhanced efficacy
AU2005224079A1 (en) * 2004-03-15 2005-09-29 Anormed, Inc. Process for the synthesis of a CXCR4 antagonist

Also Published As

Publication number Publication date
EP1789045A2 (en) 2007-05-30
WO2006023400A3 (en) 2006-06-08
RU2350604C2 (ru) 2009-03-27
AR050522A1 (es) 2006-11-01
CA2577100A1 (en) 2006-03-02
CN101039672A (zh) 2007-09-19
MX2007001958A (es) 2007-05-09
JP2008510006A (ja) 2008-04-03
IL181160A0 (en) 2007-07-04
ZA200701282B (en) 2010-05-26
BRPI0514438A (pt) 2008-06-10
US20080045537A1 (en) 2008-02-21
MA28814B1 (fr) 2007-08-01
AU2005277638A1 (en) 2006-03-02
TW200619217A (en) 2006-06-16
WO2006023400A2 (en) 2006-03-02
KR20070042568A (ko) 2007-04-23
NO20071161L (no) 2007-05-14
RU2007105823A (ru) 2008-09-27

Similar Documents

Publication Publication Date Title
PE20060646A1 (es) Derivados de bencimidazol como moduladores de la actividad de quimioquinas
PE20060656A1 (es) COMPUESTOS DE IMIDAZO[1,2-a]PIRIDINIL COMO MODULADORES DE LA ACTIVIDAD DE QUIMIOQUINAS
BR0309118A (pt) Derivados de tropano úteis em terapêutica
BR0110767A (pt) Derivados de piperidina farmaceuticamente ativos, em particular como moduladores da atividade de receptor de quimiocina
PE20110679A1 (es) Derivados de (4-tert-butilfenil)pirrolidin-2,5-difenil como inhibidores del hcv
BRPI0414862A (pt) derivados de tropano substituìdos com imidazopiridina com atividade antagonista do receptor ccr5, para o tratamento do hiv e da inflamação
PE20090816A1 (es) Derivados de pirrolopirimidinona como agentes ligandos de los receptores p2x3
UY29301A1 (es) Derivados amida
EA200700117A1 (ru) N-замещенные пиперидины и их применение в качестве фармацевтических препаратов
NO20070981L (no) Substituerte oksazolidinoner og deres anvendelse innenfor feltet blodkoagulasjon.
BR112012008518A2 (pt) derivado heterocíclico, e, composição farmacêutica
BRPI0616077B8 (pt) composição farmacêutica formulada em uma dose única, kit, artigo de manufatura, uso da composição farmacêutica e uso de um ou mais compostos antidiabéticos
NO20066041L (no) Anvendelse av substituerte kinolinderivater for behandlingen og legemiddelresistente mykobakterielle sykdommer
GEP20084505B (en) 3-cycloalkylaminopyrrolidine derivatives as modulators of chemokine receptors
TW200635904A (en) Fused pyrazole derivatives and methods of treatment of metabolic-related disorders thereof
HRP20100664T1 (hr) Upotreba 3-(4-amino-1-okso-1,3-dihidroizoindol-2-il)piperidin-2,6-diona u lijecenju limfoma stanica plasta
WO2005101989A3 (en) Piperidine derivatives as modulators of chemokine receptor ccr5
UA112055C2 (uk) Солі 4-[2-[[5-метил-1-(2-нафталініл)-1h-піразол-3-іл]оксі]етил]морфоліну
NO20085271L (no) Muscarin reseptoragonister som er effektive i behandling av smerte, Alzheimers sykdom og schizofreni
TW200616635A (en) Novel compounds
BR0308592A (pt) Derivados de piperidina ou 8-azabiciclo [3.2.1] oct-3-il-piperidina, de utilidade como moduladores da atividade do receptor de quimocina (especialmente ccr5)
ECSP23053033A (es) N-(2-(4-cianotiazolidin-3-il)-2-oxoetil)-quinolin-4-carboxamidas
BR0317459A (pt) Novos derivados de piperidina como moduladores do receptor ccr5 quimiocina
PE20060869A1 (es) Sulfonamido-macrociclos y sus sales como inhibidores de tie2 y composiciones farmaceuticas que comprenden estos compuestos
PE20090115A1 (es) Derivados de indol-2-il-piperazin-1-il-metanona

Legal Events

Date Code Title Description
FC Refusal